
Bempedoic acid, sold as Nexletol, is an oral non-statin medicine that lowers LDL cholesterol and can reduce cardiovascular events in certain higher-risk adults who cannot take recommended statin therapy. The usual dose is 180 mg once daily. It works in the liver by blocking ATP-citrate lyase, an enzyme upstream of the pathway targeted by statins.
Its main advantage is that it offers meaningful LDL reduction without being activated in skeletal muscle, which may be useful for people who have had troublesome statin-associated muscle symptoms. In the CLEAR Outcomes trial, bempedoic acid lowered LDL by about 21% compared with placebo at six months and reduced the risk of the primary composite cardiovascular outcome by 13% over a median 40.6 months. It is not side-effect free. Gout, higher uric acid, gallstones, liver-enzyme changes, and tendon problems are important considerations, so the choice should be individualized.
Table of Contents
- Who Bempedoic Acid Is For
- How It Works and How Much It Lowers LDL
- Cardiovascular Benefits From CLEAR Outcomes
- Side Effects and Warnings
- Dose, Monitoring, and Drug Interactions
- Bempedoic Acid vs Other Non-Statin Options
- Questions to Ask Before Starting Nexletol
Who Bempedoic Acid Is For
Nexletol is indicated to reduce LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, and the current U.S. prescribing information also includes reduction of major adverse cardiovascular events in adults at increased risk who are unable to take recommended statin therapy, including people not taking a statin.
In practice, it is often considered when LDL remains above target because a person cannot tolerate an adequate statin dose, needs additional LDL lowering beyond what is achieved with tolerated therapy, or prefers an oral option. Some people take it with ezetimibe; a fixed-dose combination of bempedoic acid plus ezetimibe is sold separately as Nexlizet.
Bempedoic acid does not automatically replace statins. Statins remain first-line therapy for many patients because of their strong LDL-lowering effect, low cost, and extensive cardiovascular outcome evidence. If symptoms occur with one statin, clinicians often try a different statin, a lower dose, or intermittent dosing before declaring complete intolerance.
If you are comparing options after statin problems, statin alternatives such as ezetimibe, PCSK9 therapy, and bempedoic acid differ in LDL reduction, route, cost, and evidence. The best choice depends on how far LDL needs to fall and how high your cardiovascular risk is.
How It Works and How Much It Lowers LDL
Bempedoic acid inhibits ATP-citrate lyase, or ACL, in the liver. ACL sits upstream of HMG-CoA reductase, the enzyme blocked by statins. Inhibiting cholesterol synthesis increases LDL receptor activity in the liver, which helps remove LDL particles from the bloodstream.
A key pharmacology feature is that bempedoic acid requires activation by an enzyme that is present mainly in the liver and not in skeletal muscle. That is one reason muscle-related side effects may be less prominent than with statins, although muscle symptoms can still occur for many reasons and no drug is completely symptom-free.
Average LDL reduction depends on background therapy. Reviews estimate roughly an 18% reduction when bempedoic acid is added to statin therapy and around 20% to 25% in statin-intolerant patients. Combining it with ezetimibe can produce a substantially larger reduction, often around the high-30% range.
The absolute drop matters more than the percentage alone. If LDL is 160 mg/dL, a 20% reduction is about 32 mg/dL, leaving LDL near 128 mg/dL. For a person who needs LDL below 70 mg/dL or lower, bempedoic acid alone may not be enough. That is why treatment is often layered rather than chosen as a single “winner.”
Cardiovascular Benefits From CLEAR Outcomes
CLEAR Outcomes changed the role of bempedoic acid because it tested cardiovascular events rather than cholesterol numbers alone. The trial enrolled 13,970 statin-intolerant adults who had cardiovascular disease or were at high risk for it. Participants received bempedoic acid 180 mg daily or placebo and were followed for a median of 40.6 months.
At six months, LDL was about 21 percentage points lower with bempedoic acid than with placebo. The primary outcome—cardiovascular death, nonfatal heart attack, nonfatal stroke, or coronary revascularization—occurred in 11.7% of the bempedoic acid group and 13.3% of the placebo group. That corresponds to a hazard ratio of 0.87, or about a 13% relative risk reduction.
The trial showed significant reductions in heart attack and coronary revascularization, but not a significant reduction in all-cause death. A prespecified analysis later found fewer total cardiovascular events as well.
These results are important but should be interpreted in the studied population: people with elevated LDL and inability or unwillingness to take guideline-recommended statins. They do not mean every person with mildly elevated cholesterol needs bempedoic acid. The expected benefit rises as baseline cardiovascular risk rises.
Side Effects and Warnings
The most important adverse effects are increases in uric acid and gout, gallstones, liver-enzyme changes, and tendon injury. In CLEAR Outcomes, gout occurred more often with bempedoic acid than placebo, around 3% versus 2%. Uric acid can rise early and may remain elevated during treatment.
People with a history of gout deserve special attention. A clinician may check uric acid before or after starting therapy and ask about joint pain, redness, and swelling. Gallstones were also somewhat more common in the bempedoic-acid group.
Tendon rupture is included in prescribing warnings. Risk may be higher in older adults and people with additional tendon-risk factors. New tendon pain or swelling—especially around the Achilles tendon, shoulder, or biceps—should be evaluated promptly. Current prescribing information notes that tendon-related events occurred in trials, although the detailed CLEAR Outcomes safety analysis found similar rates of tendinopathy-related events between groups.
Liver enzymes and creatinine can change modestly. Clinicians decide whether baseline or follow-up testing is needed based on the person’s history and other medicines. Serious hypersensitivity is a contraindication.
Compared with statins, bempedoic acid generally causes fewer concerns about direct skeletal-muscle exposure, but it should not be marketed as a “no side effects” drug.
Dose, Monitoring, and Drug Interactions
The usual Nexletol dose is 180 mg once daily, with or without food. The current label recommends checking lipid levels within about 8–12 weeks after starting to see whether the LDL response is adequate.
Bempedoic acid can interact with certain statins by increasing statin concentrations. The prescribing information limits concomitant simvastatin to 20 mg daily and pravastatin to 40 mg daily unless the potential benefit outweighs the risk. If you are taking any statin with bempedoic acid, the prescriber should review the dose and monitor for muscle symptoms.
A practical monitoring plan often includes:
- a baseline lipid panel and repeat panel after 8–12 weeks;
- review of gout history and uric acid when clinically appropriate;
- attention to tendon symptoms;
- liver tests if symptoms or risk factors suggest a problem;
- review of the full medication list for interactions.
Do not judge effectiveness by how you feel. High LDL usually causes no symptoms. The relevant question is whether LDL or ApoB falls enough to reach a risk-appropriate target.
If you are confused by cholesterol targets, cholesterol ranges and treatment targets can help explain why the “right” LDL differs by risk level.
Bempedoic Acid vs Other Non-Statin Options
Ezetimibe is another oral non-statin drug and often lowers LDL by about 15%–20%. It is inexpensive as a generic and is commonly the first add-on to a statin. Bempedoic acid provides a similar or somewhat greater reduction in many statin-intolerant patients and has dedicated outcomes data in that population. The two can be combined for a larger effect.
PCSK9 monoclonal antibodies and inclisiran can lower LDL much more—often around 50% or more—but they are injectable and usually cost more. Choice therefore depends on the LDL gap, insurance coverage, willingness to use injections, and prior medication history.
For someone with LDL only modestly above target, an oral option may be enough. For someone with familial hypercholesterolemia or established atherosclerotic cardiovascular disease who needs a large absolute reduction, a more potent injectable agent may be appropriate.
The treatment conversation should also include statin rechallenge when reasonable. If prior symptoms were muscle-related, statin muscle pain strategies can sometimes identify a dose or drug that is tolerable. Even a small tolerated statin dose can be useful when combined with non-statin therapy.
Questions to Ask Before Starting Nexletol
Before starting bempedoic acid, ask what LDL target you are trying to reach and how much lowering is expected from the drug. If the expected reduction will not get you close to target, it may make more sense to plan combination therapy from the start.
Also ask about your gout risk, uric acid, tendon history, and current statin dose. Tell the prescriber if you have had recurrent gout, tendon rupture, significant liver disease, or serious drug allergies. Pregnancy should also be discussed because cholesterol-lowering therapy is generally approached differently during pregnancy.
Cost and adherence matter. An oral medicine only works if you can obtain and take it consistently. If coverage is poor, a different medication may be more practical even if the pharmacology looks ideal on paper.
Finally, remember that medication is one part of risk reduction. Blood pressure, smoking, diabetes, physical activity, sleep, diet, and weight can materially alter cardiovascular risk. Bempedoic acid is best viewed as a targeted LDL-lowering tool within a broader plan, not as a replacement for lifestyle or follow-up care.
Absolute risk reduction is useful when deciding whether treatment is worth it. In CLEAR Outcomes, the primary event rate was 13.3% with placebo and 11.7% with bempedoic acid over roughly 3.4 years. That is an absolute difference of 1.6 percentage points in the trial population. People at lower baseline risk would be expected to have a smaller absolute benefit over the same period, while people at higher risk may gain more.
LDL response can also vary. If your LDL falls much less than expected, first check adherence and whether you are taking the medicine consistently. If the response is still inadequate, the answer may be combination therapy rather than simply waiting longer.
Side-effect discussions should stay balanced. Gout and uric-acid increases are real, but many people tolerate the drug well. The decision is a tradeoff between expected cardiovascular benefit, LDL reduction, side-effect risk, cost, and available alternatives.
Why Statin Intolerance Needs Careful Evaluation
Many people report muscle symptoms while taking statins, but not every ache is caused by the drug. Thyroid disease, vitamin deficiencies, strenuous exercise, drug interactions, and ordinary musculoskeletal problems can look similar. A structured statin-intolerance evaluation may involve stopping the drug briefly, checking symptoms, and trying a different statin or dose when appropriate.
This matters because even a small tolerated statin dose can add meaningful LDL reduction and may be combined with bempedoic acid or ezetimibe. Complete statin intolerance is less common than partial intolerance. The goal is not to force a drug that makes someone miserable; it is to avoid giving up on an effective class before reasonable alternatives have been tested.
CLEAR Outcomes enrolled people who were unable or unwilling to take guideline-recommended statin therapy because of unacceptable adverse effects. That makes its results particularly relevant to this group, but it also means the trial does not prove that bempedoic acid is superior to statins in people who tolerate statins well.
What Happens if You Combine It With Ezetimibe?
Bempedoic acid and ezetimibe work through different mechanisms, so their LDL-lowering effects can be additive. Reviews estimate that the fixed-dose combination can lower LDL by roughly the high-30% range in many patients. This may be enough for someone who needs a moderate additional reduction but wants to stay with oral medicines.
The combination is not automatically the best choice. A person who needs a 60% reduction may still require a PCSK9 inhibitor or another potent therapy. Conversely, someone who needs only a 10%–15% reduction may do well with ezetimibe alone. Starting with the LDL gap avoids unnecessary complexity.
Combination therapy also means reviewing side effects and cost from both medicines. Ezetimibe is generally well tolerated, while bempedoic acid adds the uric-acid, gout, gallstone, and tendon considerations discussed above. Insurance formularies can strongly influence which sequence is practical.
How to Think About Gout and Uric Acid
Bempedoic acid can raise uric acid because of effects on renal handling. People with prior gout have a higher baseline risk of another attack, so history matters. A mildly elevated uric-acid number alone does not guarantee gout, but a sudden red, swollen, exquisitely painful joint—often the big toe, ankle, or knee—should be evaluated promptly.
Do not stop the drug permanently after one symptom without speaking to the prescriber, but do not ignore a suspected gout attack either. Depending on cardiovascular need and gout severity, clinicians may treat the gout, adjust other medications, or choose a different LDL-lowering strategy.
Hydration and weight management may help gout risk, but they do not eliminate a medication effect. Some diuretics can also raise uric acid, making the full medication list important. A coordinated plan is more useful than judging bempedoic acid in isolation.
What to Do if LDL Is Still Above Goal
If LDL remains high after 8–12 weeks, confirm adherence and repeat the lipid panel under usual conditions. Then quantify the remaining gap. A person at 115 mg/dL with a goal below 70 mg/dL needs a very different next step from someone at 82 mg/dL with the same target.
Options include adding ezetimibe, using a PCSK9 monoclonal antibody, considering inclisiran where appropriate, or revisiting a low-dose statin. The best sequence depends on risk, cost, convenience, and expected percentage reduction. Do not simply wait for bempedoic acid to become more potent over time; most of its LDL effect is apparent within weeks.
Pregnancy, Breastfeeding, and Other Special Situations
Cholesterol-lowering treatment is handled differently during pregnancy. The current Nexletol prescribing information advises patients to tell their clinician about a known or suspected pregnancy, and treatment decisions should be individualized. Do not continue or stop the medicine on your own if pregnancy occurs. Breastfeeding decisions also require clinician input because the balance between maternal cardiovascular need and infant exposure differs by situation.
Older adults can use bempedoic acid, but gout and tendon history become especially relevant because those problems are more common with age. People with multiple chronic conditions should also review the full medication list rather than treating LDL therapy in isolation.
If you are scheduled for surgery or develop a major acute illness, keep all prescribers informed about your cholesterol medicines. Medication reconciliation prevents duplicate therapy and helps clinicians interpret laboratory changes correctly.
The most useful way to apply this information is to make one change, measure the result, and then decide whether it deserves a permanent place in your routine. Cardiovascular risk factors respond to the total pattern over time, so a modest intervention can still be worthwhile when it is safe, affordable, and easy to sustain. At the same time, do not let a modest food or supplement effect delay treatment that has stronger evidence when your risk is high.
Keep records simple: note the product or food amount, the dates you used it, relevant home measurements, and the next lab value or clinic reading. This prevents memory from exaggerating benefits or side effects. If the expected benefit does not appear after a reasonable trial, reassess rather than automatically increasing the dose. If it does help, keep the rest of the plan in place—diet quality, physical activity, sleep, smoking avoidance, and prescribed treatment remain the foundation of cardiovascular prevention.
References
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients 2023 (RCT)
- Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial 2024 (RCT)
- Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials 2024 (Systematic Review)
- Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance 2024 (Analysis)
- NEXLETOL- bempedoic acid tablet, film coated 2026 (Prescribing Information)
Disclaimer
Bempedoic acid is a prescription medicine and requires individualized medical guidance. Do not start, stop, or change cholesterol medicines based on this article alone; discuss LDL goals, gout risk, tendon symptoms, interactions, pregnancy, and follow-up testing with your prescriber.





